ArticleTobacco control2025
Use of nicotine pouches among adults who currently or formerly smoked cigarettes and/or vaped nicotine: findings from the 2022 and 2024 US ITC smoking and vaping surveys.
Article in Tobacco control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNicotine pouches (NPs) are one of the fastest growing tobacco product categories in the United States (US). We estimated the prevalence of NP use in 2022 and 2024 among US adults with established nicotine product use.
methodsData are from the 2022 (n=2087) and 2024 (n=2083) US ITC Smoking and Vaping Surveys. A nationally representative sample of adults (≥18 years) who smoked cigarettes and/or vaped nicotine or quit smoking and/or vaping completed at least one survey. Using weighted data, generalised estimating equation models were applied to estimate ever-use and current use (≥monthly). Data from both surveys were pooled to examine characteristics related to NP ever-use and current use.
resultsBetween 2022 and 2024, the prevalence of NP ever-use increased by 42% (16.1%-22.8%, p<0.001), and current use increased by 66% (4.7%-7.8%, p=0.007). NP ever-use increased significantly among all age groups, except adults aged 25-39. Current use increased among all age groups, but only significantly for adults aged 18-24 and 55+. Compared with all other age groups, adults aged 18-24 had an 11.8% greater increase in current use (p=0.045). In the pooled analyses, current NP use was significantly higher among those who were male, were using other smokeless tobacco products (p<0.001), were smoking and vaping (dual use), exclusively vaping or had quit smoking and/or vaping compared with adults who were exclusively smoking (p<0.001). There were non-significant increases in frequency of daily, non-daily and occasional use.
conclusionsWe found a significant increase in NP ever-use and current use between 2022 and 2024 among adults with established nicotine product use, consistent with national sales trends. Further research is needed to determine whether adults are using NPs as a tool to quit smoking or sustain abstinence after quitting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.